News

iWatchz introduces watch bands for iPod Nano

BY Allison Cerra

NEW YORK — A line of watch bands that allows users to sport their iPod Nano like a watch has hit retail.

iWatchz offers nine collections of Nano watch bands, all of which tout the iWatchz patent-pending clip system, offering a snug and secure fit for the iPod Nano. The bands range from vibrant silicone to soft-touch leather to stainless steel links to cater to every style-conscious music lover, the company said.

Retailing for $24.99 and up, iWatchz Nano watch bands are available at various stores, including Target, Apple, Best Buy, Amazon.com and iWatchz.com.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Pfizer pain drug doesn’t affect sperm production, study finds

BY Alaric DeArment

NEW YORK — A drug made by Pfizer for treating pain disorders doesn’t affect men’s reproductive functions, according to a new post-approval clinical study.

The drug maker announced Monday the results of study A0081104 of Lyrica (pregabalin), which compared the drug with placebo in healthy males to assess its effects on sperm production. The phase-4 study was required by the Food and Drug Administration.

The study enrolled 222 men, who were randomly selected to receive either the drug or placebo. Lyrica is used to treat post-herpetic neuralgia, diabetic nerve pain, fibromyalgia, neuropathic pain associated with spinal cord injury and partial-onset seizures in certain adults with epilepsy.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

With Walgreens’ and ESI’s new deal, September will be about battle for the pharmacy patient

BY Michael Johnsen

WHAT IT MEANS AND WHY IT’S IMPORTANT — Prepare to roll up your sleeves, because the battle for the ESI patient has only just begun. While Wall Street is busy calculating the earnings-per-share impact this will have on all relevant parties (Walgreens’ stock is still trading up some $3, an approximate 10% increase, since the announcement), the business of pharmacy retailing will return to block and tackle mode. Filling prescriptions across the back-bench may have become a commodity, but that pharmacy patient still holds tremendous value. And beginning Sept. 15, CVS, Rite Aid and all others who captured Walgreens patients out of this dispute will be fighting to keep them while Walgreens makes a concerted effort to win them back.

(THE NEWS: Walgreens, Express Scripts end dispute. For the full story, click here.)

And what does that mean? It means the inherent pharmacy value proposition is going to be hyped by all of the major players to the "nth" degree. Walgreens is launching its loyalty card in September, so the Chicago-based retailer already had planned to kick its marketing up another notch. And Rite Aid already may have something in the works for its very much successful Wellness+ loyalty program — analysts in June attempted to tease out what those plans were during Rite Aid’s last conference call, but Rite Aid’s John Standley declined to reveal his hand: "We can’t give away all of our secrets."

But pharmacy’s secret sauce will share many of the same ingredients across all of the chains, including ever-evolving patient interaction/interception programs to help mitigate noncompliance and improve outcomes. There’s also immunizations, a healthcare offering that has fast become a staple across retail pharmacy. And now loyalty cards. Between CVS’ ExtraCare card, Rite Aid’s Wellness+ and Walgreens’ yet-to-be-unveiled card that surely will benefit from its recent Alliance Boots relationship, patients will be given a host of reasons to visit their pharmacy come September.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?